Morning Trend | GRANDPHARMA consolidates with reduced volume, can the key support hold?

On December 17th, GRANDPHARMA (512.HK) continued to consolidate weakly, with low trading activity throughout the day and funds remaining cautious. The significant fluctuations during the session lacked strong participation from major players, the MACD death cross remains unresolved, and the moving average system is entirely bearish. The short-term market relies on support at the 5.06 yuan level. There is a scarcity of excitement in the industry sector, with slow progress in new drug approvals and policy changes. Although there were news about local access for innovative drugs this week, the details have not been finalized, and the enthusiasm for fund participation has not been ignited. The leading stocks in the sector continue to observe, and small-cap stocks see quick rises during the session followed by profit-taking. Key attention should be paid to the gains and losses of support levels and changes in intraday volume; a simultaneous rise in volume and price is a necessary condition for a rebound. The overall market lacks a leading trend, and short-term focus should be on unusual movements by major players and marginal policy events. If no substantial signals are observed, it is recommended that investors remain cautious, avoid chasing prices, and steer clear of the risk of secondary declines caused by breaking support